Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.
Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.
1457 of 1457 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
PRECISION BIOSCIENCES INCDTIL · Nasdaq | 1 asset: 1 Ph 1 | Azercabtagene zapreleucelPhase 1 · Multiple Sclerosis | 1 Dec 2026Azercabtagene zapreleucel · Phase 1 | $198M | $108MSep 2026 | ~8.4 qtrs | $53M |
Cartesian Therapeutics, Inc.RNAC · Nasdaq | 1 asset: 1 Ph 3 | Descartes-08Phase 3 · Myasthenia Gravis | 1 Dec 2026Descartes-08 · Phase 2 | $192M | $125MSep 2026 | ~5.6 qtrs | $70M |
Alpha Cognition Inc.ACOG · Nasdaq | 1 asset: 1 approved | Approved assets only | Apr 2027Benzgalantamine · Approved | $187M | $38MSep 2026 | ~5.0 qtrs | $5.0M |
COMPUGEN LTDCGEN · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | RilvegostomigPhase 3 · Non-Small Cell Lung Cancer | Mar 2027COM701 · Phase 1/2 | $185M | $100MDec 2025 | Cash-flow positive | $23M |
Inovio Pharmaceuticals, Inc.INO · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | $175M | $48MSep 2026 | ~2.6 qtrs | $46M |
Pyxis OncologyPYXS · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | MW02Phase 2/3 · Age-Related Macular DegenerationPartial signal | 25 Apr 2027Micvotabart pelidotin · Phase 1 | $168M | $56MSep 2026 | ~8.9 qtrswith a later raise | $74M |
Xilio TherapeuticsXLO · Nasdaq | 1 asset: 1 Ph 2 | XTX501Phase 1/2 · Non-Small Cell Lung Cancer | Nov 2029XTX501 · Phase 1/2 | $154M | $124MSep 2026 | ~8.7 qtrs | $67M |
| 3 assets: 3 Ph 1 | BBO-10203Phase 1 · Non-Small Cell Lung Cancer | Aug 2027BBO-10203 · Phase 1 | $145M | $194MSep 2026 | ~5.1 qtrs | $157M | |
Sutro Biopharma, Inc.STRO · Nasdaq | 1 asset: 1 Ph 1 | STRO-004Phase 1 · Non-Small Cell Lung Cancer | Dec 2027STRO-004 · Phase 1 | $141M | $142MSep 2026 | ~4.4 qtrs | $128M |
HumacyteHUMA · Nasdaq | 1 asset: 1 approved | Approved assets only | Jun 2027Human Acellular Vessel (Humacyte) · Phase 3 | $139M | $65MSep 2026 | ~2.9 qtrs | $66M |
ALX Oncology Inc.ALXO · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | EvorpaceptPhase 2 · HER2-Positive Breast Cancer | Jun 2027ALX2004 · Phase 1 | $134M | $138MJun 2026 | ~7.8 qtrs | $62M |
Protara TherapeuticsTARA · Nasdaq | 1 asset: 1 Ph 3 | TARA-002Phase 3 · Non-Muscle Invasive Bladder Cancer | Dec 2026TARA-002 · Phase 2 | $132M | $128MSep 2026 | ~7.1 qtrs | $60M |
MacroGenicsMGNX · Nasdaq | 5 assets: 1 Ph 2, 4 Ph 1 | LorigerlimabPhase 2 | Nov 2026MGD024 · Phase 1 | $125M | $49MSep 2026 | ~4.9 qtrs | $138M |
Fate TherapeuticsFATE · Nasdaq | 4 assets: 1 Ph 2, 2 Ph 1, 1 other | FT819Phase 2 · Systemic Lupus Erythematosus | 30 Sep 2027FT819 · Phase 1 | $122M | $139MSep 2026 | ~5.3 qtrs | $99M |
NRx PharmaceuticalsNRXP · Nasdaq | 1 asset: 1 Ph 3 | D-cycloserine/lurasidone (NRX-101)Phase 3 · Bipolar Depression | None on record | $121M | $27MJun 2026 | ~5.4 qtrs | $5.4M |
Upstream BioUPB · Nasdaq | 1 asset: 1 Ph 2 | verekitugPhase 2 · Chronic Obstructive Pulmonary DiseaseReliable signal | Sep 2027verekitug · Phase 2 | $114M | $207MSep 2026 | ~4.9 qtrs | $149M |
Akebia TherapeuticsAKBA · Nasdaq | 3 assets: 1 approved, 2 Ph 2 | Ebribafusp alfaPhase 2 · IgA Nephropathy | Jun 2027Praliciguat · Phase 2 | $114M | $160MSep 2026 | Cash-flow positive | $72M |
Compass TherapeuticsCMPX · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | tovecimigPhase 2/3 · Biliary Tract Cancer | Dec 2026CTX-8371 · Phase 1 | $110M | $163MSep 2026 | ~10.6 qtrs | $69M |
Minerva NeurosciencesNERV · Nasdaq | 1 asset: 1 Ph 3 | RoluperidonePhase 3 · SchizophreniaPartial signal | Dec 2027Roluperidone · Phase 3 | $109M | $77MSep 2026 | ~9.8 qtrs | $20M |
Neonc Technologies, Inc.NTHI · Nasdaq | 2 assets: 1 Ph 2, 1 other | NEO212Phase 1/2 · Non-Small Cell Lung Cancer | 30 Dec 2026NEO100 · Phase 2 | $108M | $6.2MSep 2026 | ~1.2 qtrs | $6.5M |
Lexaria BioscienceLEXX · Nasdaq | 2 assets: 1 Ph 1, 1 other | DehydraTECH-CBD/semaglutidePhase 1 · ObesityWeak signal | None on record | $106M | $3.6MMay 2026 | Ended Oct 2026 | $5.3M |
NovaBridge BiosciencesNBP · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | UliledlimabPhase 2/3 · Non-Small Cell Lung Cancer | Dec 2026givastomig · Phase 1 | $104M | $211MDec 2025 | ~38.3 qtrs | $63M |
Voyager TherapeuticsVYGR · Nasdaq | 1 asset: 1 Ph 2 | VY7523Phase 1/2 · Alzheimer's Disease | None on record | $104M | $110MSep 2026 | ~4.0 qtrs | $107M |
Genelux CorporationGNLX · Nasdaq | 1 asset: 1 Ph 3 | Olvimulogene nanivacirepvecPhase 3 · Ovarian Cancer | Dec 2026Olvimulogene nanivacirepvec · Phase 3 | $101M | $19MJun 2026 | ~3.0 qtrs | $23M |
Unicycive TherapeuticsUNCY · Nasdaq | 1 asset: 1 Ph 2 | Oxylanthanum carbonatePhase 2 · Chronic Kidney DiseaseWeak signal | None on record | $99M | $61MJun 2026 | ~8.8 qtrs | $9.6M |
Cumberland Pharmaceuticals Inc.CPIX · Nasdaq | 1 asset: 1 Ph 2 | IfetrobanPhase 2 · Systemic SclerosisPartial signal | Jan 2028Ifetroban · Phase 2 | $99M | $81MSep 2026 | 10+ years | $4.6M |
PMV Pharmaceuticals, IncPMVP · | 1 asset: 1 Ph 2 | rezatapoptPhase 1/2 · Non-Small Cell Lung Cancer | 15 Dec 2026rezatapopt · Phase 1/2 | $92M | $103MSep 2026 | ~5.9 qtrs | $62M |
TuHURA BiosciencesHURA · Nasdaq | 1 asset: 1 Ph 3 | IFx-2.0Phase 2/3 · Merkel Cell Carcinoma | 31 Mar 2027IFx-2.0 · Phase 2/3 | $87M | $1.9MSep 2026 | Ended Oct 2026 | $22M |
RANI TherapeuticsRANI · Nasdaq | 1 asset: 1 Ph 1 | RT-114Phase 1 | 1 Dec 2026RT-114 · Phase 1 | $80M | $3.8MSep 2026 | ~0.7 qtrs | $21M |
Maia BiotechnologyMAIA · NYSE | 1 asset: 1 Ph 3 | Ateganosine (THIO)Phase 3 · Non-Small Cell Lung Cancer | 31 Jul 2027Ateganosine (THIO) · Phase 3 | $79M | $0Sep 2026 | Ended Sep 2026 | -$2.7M |
Tenax TherapeuticsTENX · Nasdaq | 1 asset: 1 Ph 3 | LevosimendanPhase 3 · Heart FailurePartial signal | 30 Jun 2028Levosimendan · Phase 3 | $77M | $114MSep 2026 | ~9.2 qtrs | $47M |
Neumora Therapeutics, Inc.NMRA · Nasdaq | 1 asset: 1 Ph 1 | NMRA-323511Phase 1 · Alzheimer's DiseasePartial signal | None on record | $69M | $117MJun 2026 | ~2.6 qtrs | $153M |
Anavex Life SciencesAVXL · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | BlarcamesinePhase 2/3 · Alzheimer's DiseasePartial signal | None on record | $67M | $118MJun 2026 | ~13.8 qtrs | $32M |
MediciNova, Inc.MNOV · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | IbudilastPhase 2/3 · Amyotrophic Lateral Sclerosis | 31 Dec 2026Tipelukast · Phase 2 | $65M | $29MSep 2026 | ~11.9 qtrs | $4.7M |
vTv TherapeuticsVTVT · Nasdaq | 3 assets: 2 Ph 3, 1 Ph 2 | Prifemilast (HPP737)Phase 3 · PsoriasisPartial signal | Apr 2027cadisegliatin · Phase 3 | $64M | $77MSep 2026 | ~14.2 qtrs | $29M |
Coherus BioSciences, Inc.CHRS · Nasdaq | 1 asset: 1 approved | Approved assets only | 15 Dec 2026Toripalimab · Phase 1 | $63M | $84MSep 2026 | ~1.9 qtrs | $97M |
Longeveron (NASDAQ: LGVN)LGVN · Nasdaq | 1 asset: 1 Ph 2 | LaromestrocelPhase 2 · Alzheimer's DiseaseWeak signal | None on record | $60M | $7.3MSep 2026 | ~1.6 qtrs | $12M |
Cognition TherapeuticsCGTX · Nasdaq | 1 asset: 1 Ph 2 | ZervimesinePhase 2 · Alzheimer's DiseaseWeak signal | 31 May 2027Zervimesine · Phase 2 | $57M | $31MSep 2026 | ~8.2 qtrs | $27M |
Corbus PharmaceuticalsCRBP · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | Sutantatug envedotinPhase 3 · Cervical Cancer | 16 Jan 2027Sutantatug envedotin · Phase 1/2 | $57M | $115MSep 2026 | ~5.0 qtrs | $104M |
Oncolytics Biotech Inc.ONCY · Nasdaq | 1 asset: 1 Ph 2 | PelareorepPhase 2 · Advanced Metastatic Colorectal Cancer | 30 Jul 2027Pelareorep · Phase 1/2 | $56M | $2.4MSep 2026 | Ended Oct 2026 | ~$19M |
Tonix PharmaceuticalsTNXP · Nasdaq | 5 assets: 3 approved, 2 Ph 2 | TNX-1300Phase 2 · Cocaine Intoxication | Feb 2028cyclobenzaprine · Phase 2 | $55M | $163MSep 2026 | ~3.9 qtrs | $80M |
Veru Inc.VERU · Nasdaq | 1 asset: 1 Ph 2 | enobosarmPhase 2 · ObesityPartial signal | Oct 2027enobosarm · Phase 2 | $53M | $24MJun 2026 | ~3.1 qtrs | $16M |
| 2 assets: 1 Ph 2, 1 Ph 1 | WTX-330Phase 1/2 · Advanced Solid Tumors and Non-Hodgkin Lymphoma | None on record | $50M | $42MSep 2026 | ~7.0 qtrs | $23M | |
Gain Therapeutics, Inc.GANX · Nasdaq | 1 asset: 1 Ph 2 | GT-02287Phase 2 · Parkinson's Disease | 30 Jun 2028GT-02287 · Phase 2 | $49M | $12MSep 2026 | ~2.7 qtrs | $8.7M |
Clene NanomedicineCLNN · Nasdaq | 1 asset: 1 Ph 3 | CNM-Au8Phase 2/3 · Multiple SclerosisPartial signal | None on record | $48M | $10.0MSep 2026 | ~2.4 qtrs | $14M |
Apollomics Inc.APLM · Nasdaq | 1 asset: 1 Ph 3 | VebreltinibPhase 3 · Non-Small Cell Lung CancerWeak signal | 31 Dec 2026Vebreltinib · Phase 1/2 | $48M | $3.3MDec 2025 | ~4.1 qtrswith a later raise | $5.5M |
Mereo BioPharmaMREO · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | setrusumabPhase 3 · Osteogenesis ImperfectaPartial signal | Jan 2027setrusumab · Phase 3 | $46M | $26MSep 2026 | ~4.0 qtrs | $13M |
MiNK Therapeutics, Inc.INKT · Nasdaq | 1 asset: 1 Ph 2 | agenT-797Phase 2 · Gastric CancerWeak signal | Jun 2027agenT-797 · Phase 2 | $45M | $7.5MSep 2026 | ~4.2 qtrs | $6.4M |
| 1 asset: 1 Ph 1 | PLN-101095Phase 1 · Non-Small Cell Lung Cancer | Jun 2030PLN-101095 · Phase 1 | $41M | $143MSep 2026 | ~8.5 qtrs | $64M | |
Aldeyra TherapeuticsALDX · Nasdaq | 1 asset: 1 Ph 3 | reproxalapPhase 3 · Dry Eye DiseasePartial signal | None on record | $41M | $41MSep 2026 | ~8.6 qtrs | $12M |
Biomea FusionBMEA · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | IcovamenibPhase 2 · Type 2 DiabetesPartial signal | Mar 2027Icovamenib · Phase 2 | $39M | $27MSep 2026 | ~2.4 qtrs | $35M |
Skye BioscienceSKYE · Nasdaq | 1 asset: 1 Ph 2 | nimacimabPhase 2 · Obesity | None on record | $36M | $4.8MSep 2026 | ~0.6 qtrs | $25M |
Grace TherapeuticsGRCE · Nasdaq | 1 asset: 1 Ph 3 | Nimodipine (GTx-104)Phase 3 · Subarachnoid Hemorrhage | None on record | $36M | $21MSep 2026 | ~8.2 qtrs | ~$2.6M |
Annovis Bio (NYSE American: ANVS)ANVS · NYSE American | 1 asset: 1 Ph 3 | BuntanetapPhase 3 · Alzheimer's DiseasePartial signal | Dec 2027Buntanetap · Phase 3 | $36M | $2.8MSep 2026 | Ended Oct 2026 | $53M |
Serina TherapeuticsSER · NYSE American | 1 asset: 1 Ph 1 | SER-252 (PEOZ-apomorphine)Phase 1 · Parkinson's Disease | 31 Jan 2027SER-252 (PEOZ-apomorphine) · Phase 1 | $34M | $19MSep 2026 | ~3.4 qtrs | $15M |
Actinium PharmaceuticalsATNM · | 2 assets: 1 Ph 3, 1 Ph 2 | 131I-apamistamabPhase 3 · Acute Myeloid LeukemiaPartial signal | Feb 2029131I-apamistamab · Phase 2/3 | $34M | $37MJun 2026 | ~6.5 qtrs | $18M |
INmune BioINMB · Nasdaq | 1 asset: 1 Ph 2 | PegipanerminPhase 2 · Alzheimer's DiseasePartial signal | None on record | $32M | $16MSep 2026 | ~5.1 qtrs | $17M |
NextCure, Inc.NXTC · | 3 assets: 1 Ph 2, 2 Ph 1 | NC410Phase 1/2 · Colorectal Cancer | Dec 2027LNCB74 · Phase 1 | $32M | $8.7MSep 2026 | ~0.8 qtrs | $26M |
ProMIS Neurosciences, Inc.PMN · Nasdaq | 1 asset: 1 Ph 1 | PMN310Phase 1 · Alzheimer's Disease | Dec 2026PMN310 · Phase 1 | $28M | $44MSep 2026 | ~4.3 qtrs | $33M |
Pelthos Therapeutics Inc.PTHS · NYSE American | 1 asset: 1 approved | Approved assets only | None on record | $27M | $18MSep 2026 | ~2.2 qtrs | $2.2M |
Rockwell MedicalRMTI · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | $25M | $23MSep 2026 | Cash-flow positive | $0.1M |
ABVC BioPharmaABVC · Nasdaq | 1 asset: 1 Ph 2 | PDC-1421Phase 2 · Major Depressive DisorderPartial signal | 28 Feb 2028PDC-1421 · Phase 1/2 | $24M | $0.1MSep 2026 | Ended Oct 2026 | $0.1M |
CervoMed Inc.CRVO · Nasdaq | 1 asset: 1 Ph 2 | neflamapimodPhase 2 · Dementia with Lewy BodiesPartial signal | None on record | $22M | $20MSep 2026 | ~2.9 qtrs | $19M |
Enlivex TherapeuticsENLV · Nasdaq | 1 asset: 1 Ph 2 | AllocetraPhase 2 · Osteoarthritis | Feb 2027Allocetra · Phase 2 | $20M | $6.2MDec 2025 | Ended Aug 2026 | $9.2M |
Palatin TechnologiesPTN · NYSE | 3 assets: 1 Ph 3, 2 Ph 2 | PL9643Phase 3 · Dry Eye DiseasePartial signal | None on record | $20M | $7.5MJun 2026 | ~2.2 qtrs | $12M |
BeyondSpring PharmaceuticalsBYSI · Nasdaq | 1 asset: 1 Ph 3 | PlinabulinPhase 3 · Non-Small Cell Lung CancerPartial signal | 1 Jun 2029Plinabulin · Phase 3 | $19M | $6.5MJun 2026 | Ended Nov 2026 | $4.6M |
ATOSSA THERAPEUTICS, INC.ATOS · Nasdaq | 1 asset: 1 Ph 2 | (Z)-endoxifenPhase 2 · HR+/HER2- Metastatic Breast CancerPartial signal | Nov 2026(Z)-endoxifen · Phase 2 | $18M | $21MSep 2026 | ~2.3 qtrs | $19M |
Lipocine Inc.LPCN · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | $17M | $21MSep 2026 | ~8.6 qtrs | $9.5M |
| 2 assets: 2 Ph 1 | NeldaleucelPhase 1 · Relapsed/Refractory Non-Hodgkin Lymphoma | 28 Feb 2028Neldaleucel · Phase 1 | $16M | $12MJun 2026 | ~4.9 qtrs | $8.8M | |
Cellectar Biosciences, Inc.CLRB · Nasdaq | 1 asset: 1 Ph 3 | Iopofosine I-131Phase 3 · Waldenstrom's MacroglobulinemiaWeak signal | 30 Jun 2027Iopofosine I-131 · Phase 1 | $15M | $25MSep 2026 | ~4.0 qtrs | $16M |
Seres TherapeuticsMCRB · Nasdaq | 1 asset: 1 Ph 1 | SER-155Phase 1 · Bacterial Infections in Allogeneic Stem Cell Transplant | None on record | $15M | $21MSep 2026 | ~1.3 qtrs | $40M |
Allarity Therapeutics, Inc.ALLR · Nasdaq | 1 asset: 1 Ph 2 | stenoparibPhase 2 · Ovarian Cancer | Mar 2027stenoparib · Phase 2 | $14M | — | ~7.9 qtrsJun 2026 | $8.5M |
Matinas BioPharmaMTNB · Nasdaq | 1 asset: 1 Ph 3 | Amphotericin B (MAT2203)Phase 3 · Cryptococcal Meningitis | None on record | $13M | $0.8MJun 2026 | Ended Aug 2026 | $0.1M |
BioCardiaBCDA · Nasdaq | 1 asset: 1 Ph 3 | CardiAMPPhase 3 · Heart FailurePartial signal | 1 Apr 2027CardiAMP · Phase na | $12M | $2.2MSep 2026 | ~1.2 qtrs | $4.5M |
Pluri Inc.PLUR · Nasdaq | 1 asset: 1 other | PLX-PADOsteoarthritis | None on record | $11M | $9.8MSep 2026 | ~2.0 qtrs | ~$25M |
Lisata TherapeuticsLSTA · Nasdaq | 2 assets: 2 Ph 2 | MAR001Phase 2 · HypertriglyceridemiaWeak signal | Nov 2027MAR001 · Phase 2 | $11M | $283MSep 2026 | 10+ years | $8.1M |
Ainos, Inc.AIMD · Nasdaq | 1 asset: 1 other | Interferon alfa (Veldona)Oral Warts in HIV Patients | None on record | $8.9M | $1.4MJun 2026 | Ended Oct 2026 | $7.7M |
VistaGen TherapeuticsVTGN · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 other | fasedienolPhase 3 · Social Anxiety DisorderPartial signal | None on record | $8.9M | $20MSep 2026 | ~1.4 qtrs | ~$48M |
Kyntra BioKYNB · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | RoxadustatPhase 3 · Chronic Kidney DiseaseReliable signal | 30 Oct 2027Roxadustat · Phase 3 | $7.9M | $91MJun 2026 | ~9.6 qtrs | $23M |
MoleculinMBRX · Nasdaq | 1 asset: 1 Ph 3 | AnnamycinPhase 2/3 · Acute Myeloid Leukemia | Aug 2029Annamycin · Phase 2/3 | $7.2M | $7.3MSep 2026 | ~1.1 qtrs | $20M |
MetaViaMTVA · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | VanoglipelPhase 2 · MASH / NASHWeak signal | None on record | $7.1M | $8.8MSep 2026 | ~2.1 qtrs | $19M |
BioVie Inc. (NASDAQ: BIVI)BIVI · Nasdaq | 1 asset: 1 Ph 3 | BezisterimPhase 3 · Alzheimer's DiseasePartial signal | None on record | $7.1M | $7.7MSep 2026 | ~1.7 qtrs | ~$14M |
Exicure, Inc.XCUR · Nasdaq | 1 asset: 1 Ph 2 | Burixafor (TG-0054)Phase 2 · Multiple MyelomaWeak signal | None on record | $6.8M | $1.7MJun 2026 | Ended Oct 2026 | $2.0M |
Tempest TherapeuticsTPST · Nasdaq | 1 asset: 1 Ph 3 | AmezalpatPhase 3 · Hepatocellular Carcinoma | Dec 2028Amezalpat · Phase 3 | $6.2M | $0.9MSep 2026 | Ended Oct 2026 | $2.7M |
SoligenixSNGX · Nasdaq | 1 asset: 1 Ph 3 | Synthetic hypericinPhase 3Reliable signal | None on record | $5.9M | $9.0MSep 2026 | ~4.7 qtrs | $5.1M |
Kiora Pharmaceuticals, Inc.KPRX · Nasdaq | 1 asset: 1 Ph 2 | KIO-301Phase 2 · Retinitis Pigmentosa | Aug 2027KIO-301 · Phase 2 | $5.2M | $16MSep 2026 | ~8.4 qtrs | $9.1M |
Alzamend NeuroALZN · Nasdaq | 1 asset: 1 Ph 2 | Lithium salicylate/L-proline (AL001)Phase 1/2 · Alzheimer's DiseaseWeak signal | Jul 2027Lithium salicylate/L-proline (AL001) · Phase 1/2 | $5.0M | $7.6MJul 2026 | ~4.7 qtrs | ~$4.3M |
BioLineRx Ltd.BLRX · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | $5.0M | $3.3MDec 2025 | Ended Oct 2026with a later raise | $8.1M |
PulmatrixPULM · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | Itraconazole (PUR1900)Phase 2 · Allergic Bronchopulmonary Aspergillosis | None on record | $4.9M | $2.2MJun 2026 | ~2.2 qtrs | <$0.1M |
Processa Pharmaceuticals, Inc.PCSA · Nasdaq | 1 asset: 1 Ph 2 | PCS499Phase 2 · Necrobiosis Lipoidica | None on record | $4.8M | $180MSep 2026 | 10+ years | $6.4M |
Lantern Pharma Inc.LTRN · | 2 assets: 2 Ph 2 | DimesnaPhase 2 · Non-Small Cell Lung CancerPartial signal | Dec 2026Dimesna · Phase 2 | $4.7M | $7.4MJun 2026 | ~3.1 qtrswith a later raise | $8.7M |
Alaunos Therapeutics, Inc.TCRT · Nasdaq | 1 asset: 1 Ph 2 | DarinaparsinPhase 2 · Peripheral T-Cell LymphomaWeak signal | None on record | $4.4M | $0.1MJun 2026 | Ended Jul 2026 | $1.6M |
GRI Bio, Inc.GRI · Nasdaq | 1 asset: 1 other | GRI-0803Systemic Lupus Erythematosus | None on record | $2.8M | $9.5MSep 2026 | ~4.0 qtrs | $2.5M |
Senti BiosciencesSNTI · | 2 assets: 2 Ph 1 | SENTI-202Phase 1 · Acute Myeloid Leukemia | None on record | $2.7M | $7.9MJun 2026 | Ended Sep 2026 | $31M |
Jaguar HealthJAGX · Nasdaq | 1 asset: 1 approved | Approved assets only | Dec 2026Crofelemer · Phase 2/3 | $1.7M | $6.6MJun 2026 | ~3.9 qtrs | $25M |
CurisCRIS · | 1 asset: 1 Ph 2 | EmavusertibPhase 2 · Acute Myeloid Leukemia | Jul 2027Emavusertib · Phase 1/2 | $1.5M | $5.6MSep 2026 | ~0.7 qtrs | $25M |
Genprex, Inc.GNPX · Nasdaq | 1 asset: 1 Ph 2 | Quaratusugene OzeplasmidPhase 1/2 · Non-Small Cell Lung Cancer | Dec 2027Quaratusugene Ozeplasmid · Phase 1/2 | $1.4M | $15MSep 2026 | ~4.0 qtrs | $10M |
Aptevo TherapeuticsAPVO · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | ALG.APV-527Phase 1/2 · Solid Tumors | Oct 2027Mipletamig · Phase 1 | $0.8M | $9.8MJun 2026 | ~1.6 qtrs | $15M |
3D Medicines Inc.1244 · HKEX | 2 assets: 2 Ph 3 | EnvafolimabPhase 3 · Non-Small Cell Lung CancerWeak signal | Dec 2026Envafolimab · Phase 2 | — | $61MDec 2024 | ~9.6 qtrs | — |
AB ScienceAB · Euronext Paris | 2 assets: 1 Ph 3, 1 Ph 2 | MasitinibPhase 3 · Alzheimer's DiseaseReliable signal | Dec 2027Masitinib · Phase 3 | — | $10MJun 2026 | ~5.6 qtrswith a later raise | ~$20M |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.